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Statement of Clinical Relevance 
Diagnosis of Oral squamous cell carcinoma (OSCC) is based on histology of a visible 
tumour. By that time, it has become late and the tumour has become advanced grade 
and treatment outcomes become poor.  There are no biomarkers for early detection of 
OSCC tumours. We have identified a set of glycoforms of serum proteins (IgG1, 
IgG4, Haptoglobin and Transferrin) which can separate the OSCC patients from 
healthy controls. The peptide sequence, N-glycosylation site, glycan composition and 
proposed glycans structures of these glycoforms were established. Serum samples 
belonged to either stage I or IVA OSCC which were compared to healthy controls and 
it was possible to separate these patients from healthy controls based of the expression 
levels of these glycoforms. The study identifies N-glycoforms of several proteins 
which can help design sensitive future modalities for the diagnosis of OSCC patients 
as early as Stage I tumour. These glycoforms can potentially serve as sensitive 


























There are no blood biomarkers to detect early-stage oral cavity squamous cell 
carcinoma (OSCC) prior to clinical signs. Most OSCC incidence is associated with 
significant morbidity and poor survival. We aimed to use mass-spectrometry (MS) 
technology to find specific N-glycopeptides potentially serving as serum biomarkers 
for preclinical OSCC screening.  
Experimental Design 
Serum samples from 14 patients treated for OSCC (stage I or stage IV) with 12 age 
and sex-matched controls were collected. Quantitative label-free N-glycoproteomics 
was performed, with MS/MS analysis of the statistically significantly different N-
glycopeptides.  
Results 
Combined with a database search using Web-based software (GlycopeptideID), 
MS/MS provided detailed N-glycopeptide information, including glycosylation site, 
glycan composition and proposed structures. 38 tryptic N-glycopeptides were 
identified, having 19 unique N-glycosylation sites representing 14 glycoproteins. 
OSCC patients, including stage I tumors, could be differentiated from healthy controls 
based on the expression levels of these glycoforms. N-glycopeptides of IgG1, IgG4, 
Haptoglobin and Transferrin had statistically significantly different abundances 
between cases and controls.  
Conclusions and clinical relevance 
We are the first to suggest specific N-glycopeptides to serve as potential serum 
biomarkers to detect preclinical OSCC in patients. These N-glycopeptides are lead 
candidates for validation as future diagnostic modalities of OSCC as early as Stage I. 
1. Introduction 
  
Head and neck squamous cell carcinomas (HNSCCs) encompass a heterogeneous 
group of tumours. Smoking and alcohol consumption are the most common 
aetiological risk factors 
[1]
. The outcome of HNSCC patients remains poor and this is 
largely due to the fact that most of the tumours are diagnosed at an advanced stage 
[2]
. 
Although the incidence of many HNSCCs has decreased during the last decades, oral 
cavity cancers (OSCCs), and especially tongue cancers, have shown an increasing 
incidence 
[3]
. At the moment, the only and ultimate diagnostic tool for these cancers is 
a tissue biopsy from a clinically visible tumour. For early diagnosis and consequent 
better prognosis, screening of high-risk individuals or patients with ambiguous 
symptoms without clinical findings would be of great interest. Further, finding a 
specific diagnostic biomarker would make this possible.  
 
Up to 75% of serum proteins are thought to be glycosylated 
[4]
. Glycosylation is based 
on non-template biosynthesis, unlike for example RNA and protein coding 
[5]
. Under 
physiological conditions this non-linear, branching synthesis is regulated by several 
factors such as availability of monosaccharides, depending on the nutritional 
situation, and activity of the glycan-attaching and -processing enzymes 
[6]
. Despite the 
synthesis of great variety of glycoprotein types and magnitudes taking place under 
normal conditions, their distributions are thought to be stable 
[6]
. Under pathological 
conditions, aberrant glycosylation can be caused by different occupancies of 
glycosylation sites on a given protein, or by the variability of attached glycan 
structures 
[6, 7]
, leading to a specific expression of different glycovariants. In tumours, 
activity or expression levels of different glycosyltransferases or glycosidases change, 
leading to molecular changes such as modified glycan branching, sialylation or 
fucosylation 
[8]
. Another mechanism leading to altered glycosylation of proteins in 
malignancies is caused by the immune response of the host system to the ongoing 
malignant process, and thus not surprisingly, altered glycosylation patterns. Non-
specific IgGs and acute phase proteins have been shown to be present in the serum of 
patients with malignancies 
[6, 9]
. Thus, the problem of low diagnostic accuracy of 
protein biomarkers might be overcome by choosing a specific glycoprotein instead. 
Due to the challenges in both measuring and interpreting the presence and magnitude 
of glycoproteins and their altered forms, most of the glycoprotein biomarkers in use 
are based on the protein backbone - instead of the glycan moiety or glycopeptides 
themselves 
[6, 9]
. PSA and CEA are examples of the oldest and most often used 





Only a few clinical studies have previously addressed the topic of glycoproteins in 
HNSCCs before (all refs). In all these studies, either the amino acid sequence of the 
glycoprotein, or the sole glycan structure have been studied 
[11]
. Recent advances in 
quantitative high-throughput mass spectrometry (MS) have enabled the analyses of 
glycoproteins, providing simultaneous information of amino acids and glycan 
compositions, in an unknown mixture. This kind of analysis compiles information 
about multiple glycosylation sites, as well as different glycoforms of N-glycopeptides, 
and allows the estimation of putative structures of the original glycoprotein.  
Our aim was to analyse the serum samples of OSCC patients along with their age 
matched healthy controls. The aims were to separate the two groups based on their 
glycoprotein profiles, and to find specific combinations of glycopeptide attributes to 
describe this classification. 
 
 
2. Materials and Methods 
 
 
2.1 Sample collection, handling and study design 
Fourteen serum samples were collected from patients with OSCC treated at the 
Department of Otorhinolaryngology – Head and Neck Surgery, Helsinki University 
Hospital (Helsinki, Finland). An approval for the study was received from the Ethics 
Committee of Medical Sciences (Dnro: 64/13/03/02/2014) and informed consent was 
obtained from all subjects at the time of serum sample collection. Serum samples 
were stored at -70 °C until all were tested at the same time. All experiments were 
performed in accordance with relevant guidelines and regulations. Twelve age and 
sex-matched serum samples from healthy individuals serves as controls (Blood Bank, 
Helsinki). The study is case-control comparison type and retrospective in nature. The 
number of samples were chosen keeping in mind not to keep the sample size too small 
but practically manageable at the same time. Practicality involved the total number of 
patients coming to the specified clinic and meeting the requirements to be included in 
the study in a reasonable time frame. The workflow, from sample preparation to 
analysis, is represented in Figure 1. The immobilized AffiSep-SNA adsorbent was 
purchased from Galab Technologies (Geesthacht, Germany). All other lectins were 
purchased from VectorLabs (Burlingame, CA). Pierce SwellGel Blue Albumin 
Removal Discs, Pierce Centrifuge Columns (800 µL), and Pierce C18 Spin Columns 
were purchased from Thermo Scientific (Rockford, IL, USA). The high-purity HPLC 
reagents, and solvents were purchased from Waters (Milford, MA, USA). All other 
reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
2.2 Serum depletion and protein digestion 
Patient and control serum samples were thawed on ice and centrifuged at +4 C, 400 g, 
5 min to pellet precipitated proteins. The supernatant was collected to be further 
processed. Excess albumin was depleted from 50 µL of each sample by 
manufacturer’s protocol using Pierce SwellGel Blue Albumin removal discs. The 
remaining protein concentration was determined by the Pierce BCA procedure. 
Samples were dried in Savant SPD121P Speed Vac centrifugal evaporator. The 
pellets, corresponding to 350 µg total protein, were dissolved in 35 µL of 6 M urea, 
100 mM Tris-HCl pH 7.4, and reduced by adding DTT to a concentration of 10 mM, 
following incubation at room temperature (RT) for 60 min. Alkylation was performed 
by adding iodoacetamide to a concentration of 40 mM, and incubated in the dark at 
RT for 60 min. Excess iodoacetamide was consumed by adding additional DTT to a 
concentration of 30 mM and incubating at RT for 60 min. The samples were diluted 
1:10 with MQ water and trypsin was added in a mass ratio of 1:50 (trypsin to protein). 
The digestion was carried out at +37 C overnight. 
2.3 Lectin affinity chromatography 
Sixty μL of tryptic peptides were diluted by 540 μL of 10mM HEPES buffer pH 7.4 
containing 1mM CaCl2 and 1mM MnCl2. The mixture was applied to lectin-agarose 
mix column slurry containing Con-A: SNA: LCA: AAL in ratio of 5:3:3:1 for a final 
volume of lectin resin slurry of 150 μL. Micro-columns with lectin mix resins were 
incubated at 4°C on rotation overnight. Next day, 3 washes with HEPES buffer were 
performed and N-glycopeptides were eluted with sugar-mix solution containing 
fucose (100mM), α-methyl mannoside (200mM), α-methyl glucoside (200mM) and 
lactose (400mM) followed by second elution with 1% formic acid. N-glycopeptides 
were cleaned by C18 micro-columns according to manufacturer’s instructions. 
Resulting N-glycopeptides were dissolved in 0.1% formic acid before being analyzed 
by UPLC-MS. 
2.4 Ultra-performance liquid chromatography-mass spectrometry 
In glycopeptide analysis, MS processing is done in two phases: first the peptides are 
quantitated by MS
E
 run and then second MS/MS run is performed on those proteins 
with altered expression levels between the compared groups. This MS/MS run is done 
to identify the peptide sequence and potential glycan compositions. In our study, a 
web-based tool called GlycopeptideID was used to identify N-glycopeptides. 
The ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) system 
used was a Waters SYNAPT G2 High Definition MS connected to a Waters 
nanoACQUITY UPLC. The MS was run in positive mode with nano flow and a 1 
second scan time. Calibration was performed using sodium formate (over 50-2500 
m/z). The trapping column was a nanoACQUITY UPLC Trap, 180 µm × 20 mm (5 
µm), SymmetryR C18, and the analytical column was a nanoACQUITY UPLC, 75 
µm × 100 mm (1.8 µm), HSS T3. One microliter of each sample was injected. The 
LC-MS was operated in sensitivity mode with mass range 100–2000 m/z. The LC-
MS/MS was operated in sensitivity mode with mass range 50–2500 m/z The CID 
collision energy ramp was 20–60 V. The UPLC was operated under the following 
conditions: Solvent A: H2O + 0.1% formic acid, Solvent B: ACN + 0.1% formic acid. 
Flow rate 300 nL/min. Gradient: 0–1 min 1% B, 1–2 min 5% B, 2–45 min 30% B, 
45–48 min 50% B, 48– 50 min 85% B, 50–53 min 85% B, 53–54 min 1% B, 54–60 
min 1% B (Curve: 6). Total run-time was 60 min. 
2.5 Glycopeptide identification 
The MS/MS spectra were deconvoluted in Waters MassLynx 4.1 software using the 
MaxEnt3 module and saved as peak lists (file format .pkl). Identification of detected 
glycopeptides was performed on the web-based software GlycopeptideID, developed 
for automated CID MS/MS spectrum analysis 
(http://glycopeptideid.appliednumerics.fi). Although the software is revised from 
earlier versions, the principle of this method is explained in detail in two publications 
by S. Joenväärä a et al. and H. Peltoniemi et al. 
[12]
. Search functions of this software 
were also utilized in another study and described in details 
[13]
. Briefly, a database of 
tryptic peptides from known human serum proteins is generated, and the combined 
and deconvoluted MS/MS spectra are imported as peak lists. First, each spectrum is 
searched against the tryptic peptide database (Uniprot, release 04_2013, 191,896 
sequences, 3 misscleavages allowed, modifications were C alkylation fixed and M 
oxidation variable, sequence must contain NXS/T/C, X≠P) for amino acid sequence 
determination, and different possibilities are scored (peptide score). Next, possible 
glycan compositions are searched against a glycan database and resulting 
glycopeptides are fitted into the spectrum (glycan score). The total score for a 
glycopeptide hit is the sum of the peptide and glycan scores. The results are ranked, 
and for each possible result, an annotation spectrum is drawn for visual assessment of 
the matching y and b ions from peptide, glycan fragments and glycopeptide 
fragments. False-discovery rate was determined by searching the spectra against a 
reversed peptide database (target-decoy search). The false-discovery rate estimation is 
based on matches with the reverse database generated by reversed tryptic peptide 
sequences. In the resulting data, glycan compositions are given as one-letter 
abbreviations H: Hexose, N: Hexosamine, S: Sialic acid, and F: Fucose, with the 
number following showing the amount of the monosaccharides. For example, 
S1H5N4 stands for a glycan containing one sialic acid (Nacetylneuraminic acid), five 
hexoses (mannose and galactose), and four hexosamines (N-acetylglucosamine). 
Proteins are given as the UniProt entry name, e.g. HPT_HUMAN stands for human 
haptoglobin. For simplicity, we refer to identify proteins using the first part of the 
entry name in the results. These abbreviations are used throughout the text. Our final 
dataset (Supplementary Table 2B) consisted of 1556 .pkl-files (1 MS/MS spectra per 
file) collected from several separate MS/MS runs. All the annotated spectra for 
identified N-glycopeptides are provided in supplementary information. Settings used 
for searching deconvoluted peak list with GlycopeptideId were dm/z 0.05 Da for 
precursor and fragments and 50 ppm for precursors and 20 ppm for fragments. 
2.6 Data accessibility: All the relevant data is available in the supplementary 




Fourteen serum samples of patients with OSCC and 12 age and sex-matched samples 
of healthy controls were included in this study. All the patients had tongue cancers 
and they were treated with curative intent except one patient. Samples were collected 
in the operation theatre, immediately before the start of the operation for resecting the 
cancer. A Head & Neck pathologist confirmed the diagnosis for each patient 
preoperatively using a tissue biopsy. None of the patients received any treatment 
before surgery. Patient details are given in Supplementary Table 1. 
In the first MS run 5,212 potential N-glycopeptide spectra were observed and 
quantified out of which 4,094 had altered expression levels among cases and controls. 
The quantification was based on 78 runs (14 OSCC cases and 12 controls, each run in 
triplicate). After lectin affinity chromatography and the first MS run recognizing the 
potential N-glycopeptides (4,094 ions, Supplementary Table 2A) with altered 
expression levels, the second MS/MS run led to identification of 38 tryptic N-
glycopeptides (FDR 1.98%) with significantly altered serum expression levels 
between OSCC patients and controls. Figure 1 shows the principal component 
analysis (PCA) of OSCC patients and controls.  
3.1 Identified proteins  
 
When the deconvoluted spectra of the MS2 fragmented glycopeptides were searched 
against the SwissProt human tryptic peptide database (described in methods) using 
Glycopeptide ID search engine, containing the information about N-glycosylation 
consensus sites, 38 different glycoforms from 19 N-glycosylation sites and 14 
glycoproteins were identified (Supplementary Table 2B). Two conditions had to be 
met in order to the result to be considered as reliable: at least 25% of total y and b 
peptide fragment ions were found and at least three of the peptide fragment ions were 
sequential.  
 
3.2 Glycan compositions 
 
MS/MS results in fragment peaks, from which the monosaccharide compositions can 
be identified. An assessment of the structure for a glycan can also usually be drawn. A 
representative annotated spectra form the study is shown in Figure 2. Annotated 
spectra, from the output of GlycopeptideId software, of all identified N-glycopeptides 
are given in the supplemental information file named “Supplemental Annotated 
Spectra”.  
Most of the acquired glycan compositions were suggested to be bi-antennary 
complex-type structures, no high-mannose or hybrid structures were seen. Also, tri- 
and tetra-antennary structures, with possible numerous sialylation sites, were absent. 
Sixty-seven percent of all identified glycopeptides were fucosylated, 53% core-
fucosylated, and 30% sialylated. Core-fucosylated glycoforms were mostly over-
expressed (81%, fold changes ranged from 1.13-44.25), and sialylated forms mostly 
under-expressed (75%, fold changes ranged from -1.22- -5.90), in OSCC patients’ 
sera compared with that of healthy controls.   
 
3.3 Results of relative quantification 
 
Thirty-eight quantitated and identified glycoforms were among the ones which were 
found to differ between the serum samples of OSCC patients and healthy individuals 
(Supplementary Table 2).  
3.3.1 IgGs 
Immunoglobulin subspecies IgG1 was the major source of the identified peaks with 
10 ions representing seven unique glycoforms (Supplementary Table 2). When 
comparing the expression levels of these in cancer and control samples, the fold 
changes were found to vary from 9.5 to 15 being higher in cancer samples. All 
glycoforms were core-fucosylated, and core-fucosylation was found in at least five 
separate glycan fragments in the CID spectra. Among the 10 identified N-
glycopeptides of IgG1, Asp180 of IgG1 was found to be decorated with complex N-
glycans, out of which all were fucosylated except one glycopeptide which was 
sialylated (m/z 1106.518, Supplementary Table 2B). Figure 3 presents proposed 
structures associates with different m/z values of the N-glycopeptides ions having 
same peptide sequence (IgG1). Microheterogeneity can be seen at specified 
glycosylation site in the figure with at least four unique glycoforms being present. 
IgG4 (Asp177) had a core-fucosylated complex glycoform and N-glycopeptide was 
present in 2 charge states.  A core-fucosylated glycoform of IgG4 (z=4) was found to 
be expressed in 2.6 fold higher levels in cancer samples when compared with 
controls. We did not observe any significantly (FC >2) altered expression levels of 
glycosylated IgG2. Figure 4 shows the box plots of IgG1 glycopeptides expression 
levels in all samples studied. Box plot of IgG4 glycoforms expression is shown in 
Supplementary Figure 1. 
3.3.2 Transferrin and Haptoglobin  
The acute phase proteins transferrin and haptoglobin were among the glycoproteins 
with significantly altered glycoforms, when comparing OSCC serum to that of 
healthy controls. Figure 5 shows the box plot of expression levels of all glycoforms of 
haptoglobin. Supplementary Figure 2 presents the box plot of expression levels of 2 
glycoforms of transferrin. Of the haptoglobin glycoforms, all of the glycosylation site 
241, biantennal complex type with sialylation (S2H5N4) was found to have 10.9 
times higher level in cancer samples than in controls.  Significant fold change (>2) 
was not observed in the non-sialylated glycoform. In the case of Transferrin, there 
were three glycoforms of two different N-sites (432 and 630), all being sialylated and 
two also fucosylated (S2H5N4, S1H5N4F2 and S2H11N4F2), and with significantly 
lower expression (fold chages -2,4, -3,1 and -5,9) in cancer samples.  
4. Discussion  
Specific glycoforms of certain N-glycoproteins seem to be able to distinguish OSCC 
patients from healthy controls. In the current study, among the glycoproteins with 
different expression levels of the particular N-glycopeptids, sialylated structures were 
interestingly found to be mostly decreased in the OSCC samples, when comparing 
with healthy controls’ sera. Core-fucosylation was clearly more frequently present 
and fucosylated glycoforms were significantly overexpressed in OSCC compared 
with the controls.  
Examples of typical changes taking place in cancer glycoproteins are truncation and 
branching, sialylation and fucosylation. In the previous literature, a general increase 
in sialylation due to changes in specific glycosyltransferase expression has been 
linked with malignancies 
[14]
. Increased sialylation has been reported to be associated 
with poor prognosis in gastric, and colorectal carcinomas 
[15]
. Our finding of 
sialylated glycoforms being expressed in lower levels in OSCC is a novel finding of 
interest and shows that changes in glycosylation really are disease specific.  
 
Core-fucosylation is a known regulating factor of glycoproteins’ function and has 
been shown to take place in different cancers, including hepatocellular, breast and 
lung cancers 
[16]
. Hepatocellular carcinoma can be distinguished from hepatic 
infection and inflammation by a core-fucosylated alfa fetoprotein expression in serum 
[17]
.  Fucosylation of serum glycoproteins has not been studied in OSCC before. With 
this series, we were able to show that 67% of the N-glycopeptides significantly 
differentially expressed in OSCC versus healthy controls were fucosylated, and most 
of them were specifically core-fucosylated. In contrast with sialylated glycoforms, the 
fucosylated glycoforms were expressed in significantly higher levels in OSCC 
patients’ sera, when compared with that of healthy controls. 
 
A distinctive clinical problem with HNSCCs is the lack of biomarkers. During the last 
two decades, several studies have aimed to overcome this shortage 
[18]
. Guerra et al 
conducted a review of the diagnostic accuracy of different proposed serum 
biomarkers in 2015 
[18]
. In the 65 studies included, enzyme-linked immunosorbent 
assay (ELISA) was the most used method, others being microarray, quantitative 
polymerase chain reaction and liquid chromatography mass spectrometry 
[18]
. Mostly 
proteins but also DNAs, mRNAs, microRNAs and metabolites were suggested as 
potential biomarkers. From these only 13% of the single markers and 34 % of the 
panels (two or more biomarkers combined together) showed some real capacity to 
identify HNSCCs from healthy controls 
[18]
.  A main conclusion of Guerra et al was 
that none of the previously studied biomarkers seemed to be specific enough to 
reliably identify HNSCC patients. One advantage of studying serum glycopeptides as 
potential biomarkers is the significant responsiveness of their synthesis to biological 
conditions - due to their non-template biosynthesis 
[5]
.  This might offer the possibility 
to detect more disease-specific changes.  
 
In this study, we were able to quantitatively analyze the N-glycopeptide profile of the 
serum samples of OSCC patients and healthy controls. The observed serum N-
glycopeptide profiles of specifically IgG1 but also IgG4, haptoglobin and transferrin 
differed significantly between OSCC patients and healthy controls. These 
glycoproteins are typically expressed in acute phase response, and thus the interesting 
part is not their overall presence in OSCC patients’ sera but the specific glycoforms 
observed in our comparison. Analyzing the information about N-glycopeptides as 
well as their attached glycan structures and their glycosylation sites is challenging, 
and there are not many publications we could compare our results with. For example, 
no studies describing the specific glycopeptide profiles of head and neck cancers 
exist. Only one study with released serum N-glycans (as opposed to N-glycopeptides 
in our study) in OSCC has been published 
[19]
. This study had only 3 glycan 
compositions common with our study:  
Composition 1: H3N4F1 (not significantly different between OSCC cases and 
controls in previously published study). In our study, composition 1 (H3N4F1) was 
found on multiple IgG1, IgG2 and IgG4 N-glycopeptides and in IgG1 (Fold change 
14.1 and 10.5, Higher in OSCC) and IgG4 (Fold change 2.6 and 2.1, Higher in 
OSCC) it was significantly different between cases and controls.  
Composition 2: S1H5N4 (not significantly different between OSCC cases and 
controls in their study). In our study, this composition was found on 1 N-glycopeptide 
each of Hemopexin (significantly different, 1.7 times higher in OSCC cases) and 
IgA1 (Not significantly different). 
Composition 3: S2H5N4 (Significantly different between cases and controls in 
previously published study, 1.171 times lower in OSCC cases than controls). In our 
study this composition was found on 4 different N-glycopeptides (2 from 
Haptoglobin, 1 from Haptoglobin related protein and 1 form serotransferrin). 3 out of 
these 4 N-glycopeptides having this composition were singificantly different between 
OSCC cases and controls and fold changes ranged from 1.5 to 3.4.    
This comparison also highlights that although these 2 tehcniques (Glycomics and 
Glycoproteomics) are complementary to each other, they still present a different 
picture of the biological differences. One of the reasons is that in Glycomics, all 
glycans having identical compositions (masses) will be detected as one species after 
glycan release even though they might have been attached to the very different 
proteins in very different amounts. However, in Glycoproteomics, the glycans still 
remain attached to the peptides and therefore will be detected as different peaks. This 
creates the abundance difference seen in the studies comparing Glycomics and 
Glycoproteomics.   
Among other studies, two previous cancer studies analyzing a large amount of serum 
glycopeptides with label free MS in an unknown mixture have been published; one 
studying pancreas cancer vs acute pancreatitis vs healthy controls and the other 
oesophageal squamous cell carcinoma vs healthy controls 
[20, 21]
. When the 
glycoforms of IgG1, IgG4, Haptoglobin and Transferrin in OSCC patients’ sera were 
compared with those of patients with pancreatic cancer, they were found to be totally 
different 
[20]
. The oesophagus is anatomically adjacent to oral cavity and also the 
histologies of esophageal and oral cavity squamous cell carcinomas share significant 
resemblance. In the case of oesophageal cancer one of the top four glycoproteins most 
significantly separating cancer patients’ sera from those of healthy controls was 
haptoglobin 
[21]
. The glycan structure S2H5N4, with glycosylation site 241, was found 
to be significantly overexpressed in both oesophageal and oral cavity cancer 
[21]
. 
Other glycoforms of haptoglobin found in these two studies were different from each 
other as well as other glycopeptides separating these two cancers’ sera from controls. 
It seems that the specific glycoforms of glycoproteins distinguishing OSCC from 
healthy controls are specific to the disease and not just general alterations 
representing cancer. 
One of the most interesting findings of this study was that of the four glycoforms of 
IgG1 that separate OSCC from controls, all were core-fucosylated, and their 
expression levels differed starkly between groups - with fold changes ranging from 
9.5 to 15.1. We have previously studied the protein expression level changes in the 
sera of the same OSCC patients versus controls and none of the proteins found had a 
fold change over ten 
[22]
. Although in that study, we were able to find a set of serum 
proteins whose expression levels reliably distinguished OSCC patients from healthy 
controls, it thus seems that studying the expression of glycopeptides is even more 
sensitive in differentiating OSCC patients from healthy individuals. Due to the 
depletion of the 12 most abundant proteins from the serum protein analysis, aiming to 
gain a larger (dynamic) range of proteins identified, which would not otherwise be 
detected, IgGs, haptoglobin and transferrin were not included in that study. This is a 
limitation of the current study, that we are unable to make a clear comparison between 
abundance in the two studies. However, in our opinion, it is quite unlikely that the 
high fold changes found in N-glycopeptides of IgG1, IgG4, haptoglobin and 
transferrin would solely be due to protein level changes. In addition, would that be the 
case, if a certain glycoform of e.g. IgG would provide the required specificity to serve 
as a biomarker for OSCC, the underlying reason for this phenomenon would be 
secondary.  
We realize that sample size was modest in our study and it would count as potential 
limitation of the current pilot study. This was mainly due to the relatively low number 
of cases encountered at the clinic where the study based and it took approximately 2 
years to collect these samples. However, the results are significant and interesting and 
we believe it would initiate validation of results at larger centers globally. We have 
also started to collaborate with other centers in Finland and we aim to carry out future 
studies of similar nature on larger sample set.  
To conclude, we found IgG1s core-fucosylated glycoforms from serum to be able to 
distinguish OSCCs from controls. The fold changes were found to be several times 
higher than the differences found in the protein expression levels. It would be of the 
utmost importance to screen this set of glycoforms as biomarkers in a larger cohort of 
patients to establish their routine clinical use. This could be done using Multiple 
Reaction Monitoring (MRM) technology on triple quadrupole instrument 
[23]
. 
Compared with MS techniques aiming to scan through a large scale of different 
peptides/glycopeptides, this technique allows higher sensitivity and also lower 
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Figure 1: Principal component analysis (PCA).  
A. PCA of all quantified potential N-glycopeptides in Oral Squamous Cell Carcinoma 
cases and controls. PCA was performed with software Progenesis QI for Proteomics. 
In this panel, all N-glycopeptides are considered for PCA. Orange circles are cases 
and purple circles are controls. 
B. PCA of only those potential N-glycopeptides which pass the cutoff of ANOVA p 
value 0.05 in Oral Squamous Cell Carcinoma cases and controls comparison. PCA 
was performed with software Progenesis QI for Proteomics and ANOVA was 
calculated with the same. In this panel, ANOVA p value cutoff (0.05) passing N-
glycopeptides are considered for PCA. Orange circles are cases and purple circles are 
controls. 
Figure 2. Representative annotated MS/MS spectra of an N-glycopeptide.  
This figure contains the annotated MS/MS spectra of an N-glycopeptide (m/z 
1107.1462, IgG1 glycoform) with peptide sequence of TKPREEQYNSTYR and 
glycan composition of H3N5F1. Here H is a hexose, N is N-acetylglucosamine and F 
is fucose. Total Glycopeptide score (explained in methods) is 69.72 and 58% of the 
fragment intensity was explained by annotation. This spectrum is the output of 
software GlycopeptideId, which is publicly available web-based software. This 
software takes .pkl or .mgf deconvoluted spectrum files as its input. 
Figure 3: Proposed structures of the IgG1 N-glycopeptide ions.  
An N-glycopeptide of the IgG1 is shown here which was found associated with seven 
ions (m/z values of intact N-glycopeptides are indicated below the proposed 
structure). Four ions shown from left to right in the figure had unique proposed 
structures. The other 3 ions at the right side in the figure (m/z of 1039.456 (z=3), 
1093.47 (z=3) and 1107.146 (z=3)) had same proposed structures as the ones on the 
left (m/z 779.847 (z=4), 820.36 (z=4) and 830.609 (z=4) respectively). These ions had 
different m/z values because of differential amount of charges on them. The m/z 
values given are of the intact N-glycopeptide ion including the peptide part. All of 
these glycoforms were core-fucosylated and had higher expression values in OSCC 
compared to controls. The fold changes (FC) of every N-glycopeptide  ion is shown at 
the top of the proposed structure. The spectrum of these N-glycopeptide ions was 
matched to database entries (GlyycomeDB) to infer these proposed structures. It is not 
possible with current technology (CID-MS/MS) used in our experiment to infer 
linkage information (such as α- and β-glycosidic bonds), only the order of the 
attachment of monosaccharides is known. Therefore the linkage information is not 
shown n the diagram. Blue squares represent N-acetylhexosamines, green circles 
mannoses and yellow circles galactoses.   
Figure 4: Box plot of glycoforms of IgG1. 
Box plots depicting the expression levels of IgG1 glycoforms in all samples studied. 
Standard error with one sigma is shown in the graph. 
Figure 5: Box plot of glycoforms of Haptoglobin. 
Box plots depicting the expression levels of Haptoglobin glycoforms in all samples 
studied. Standard error with one sigma is shown in the graph. 
 
 
